ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy
ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy is a hedge fund based in New York, New York. According to its most recent Form D, filed Jul 15, 2026, the fund has sold $341,000 of interests to 2 investors since its first sale in Jun 2026. The minimum investment it accepts from an outside investor is $10,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Based on its first sale date and the amount raised, AltMountain classifies it as an emerging manager. Related persons named in the filing include ASA Asset Management LLC; ASA-US Building Blocks Series GP, LLC.
Performance
No verified returns have been reported for this fund. Hedge fund returns are not part of SEC filings; managers report them to AltMountain directly.
Is this your fund? Report your monthly returns · How performance works
- Total raised
- $341,000Cumulative sales reported on Form D
- Investors
- 2
- First sale
- Jun 30, 2026
- Minimum investment
- $10,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- ASA Asset Management LLC; ASA-US Building Blocks Series GP, LLC
- Latest Form D
- Jul 15, 2026
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy
What is the minimum investment for ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy?
According to its latest Form D, filed Jul 15, 2026, the minimum investment ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy accepts from an outside investor is $10,000.
Who can invest in ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy?
ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy raised?
ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy reports $341,000 sold from 2 investors on its Form D filed Jul 15, 2026. This is cumulative sales since the offering began, not current assets or performance.
Where is ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy based?
ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy is based in New York, New York and is managed by ASA Asset Management LLC.
When did ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy launch?
ASA-US Building Blocks Series, LP - ASA-US Equity Long Short Biotech Strategy reports its first sale in Jun 2026, which makes it an emerging manager by AltMountain's definition (first sale in 2021 or later and under $50 million raised).
Size compared with every hedge fund
Raised more than 10% of the 2,544 hedge funds based in New York, and more than 3% of all 10,307 that report sales.